S-1 Filing

Perceptive Capital will focus on healthcare or healthcare-related industries. In particular, the company is targeting North American or European companies in the life sciences and medical technology sectors where management has extensive investment experience. 

The new SPAC intends to focus on growing companies in Asian markets or global companies with a presence or focus in Asia, including China.

ZeroFox went public on the Nasdaq in August 2022 following a deSPAC transaction with L&F Acquisition.

YHN said it will draw on management's experience to form a business combination "that has a competitive advantage in the core business and is positioned to bring in high returns and long-term sustainable growth." The SPAC's sponsor is predominantly controlled by a Hong Kong national. YHN said it may pursue an initial business combination with a company located or doing business in China (including Hong Kong and Macau),

In addition to founding his previous Churchill Capital SPACs, CEO, President and Director Michael Klein was previously CEO of Global Banking at Citi, CEO of Citi Markets & Banking, Europe, and Co-Head of Global Investment Banking for Salomon Smith Barney for the decade prior. 

CEO and Chair Bian Fan is a senior vice president at CITIC Securities, where he leads cross-border mergers and acquisitions, and capital markets transactions. 

GP-Act III Acquisition initially filed for an offering of $250 million in March 2021. The SPAC revised its prospectus several times before withdrawing an IPO in November 2022.

The new SPAC said it will focus on the aerospace and defense services industries, particularly companies contributing to the global aerospace and defense economy. 

The SPAC had a deal with NaturalShrimp, but the seafood company terminated the merger agreement in July last year.

Biotech Group had planned to focus on the biotechnology sector in North America and the Asia-Pacific region (excluding China, Hong Kong and Macau).